Aevitas Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Aevitas Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-50	Closed	-$9K	–	342
2019 Q1	$9K	Hold	50	–	–	0.01%	311
2018 Q4	$8K	Hold	50	–	–	0.01%	324
2018 Q3	$10K	Hold	50	–	–	0.01%	345
2018 Q2	$8K	Hold	50	–	–	0.01%	344
2018 Q1	$8K	Hold	50	–	–	0.01%	344
2017 Q4	$7K	Buy	+50	New	+$7.4K	0.01%	354

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Aevitas Wealth Management's VRTX Position: Q2 2019 in Review

Aevitas Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 50 shares — an estimated $9K sold.

Aevitas Wealth Management first reported a position in VRTX in Q4 2017 and held it in 6 quarters. The position peaked at $10K in Q3 2018. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Aevitas Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Aevitas Wealth Management sold 50 Vertex Pharmaceuticals shares in Q2 2019, an estimated $9K.
Aevitas Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Aevitas Wealth Management's Vertex Pharmaceuticals position peaked at $10K in Q3 2018.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Aevitas Wealth Management's 13F filing for Q2 2019, filed 26 Jul 2019.